Houbiers J G, van der Burg S H, van de Watering L M, Tollenaar R A, Brand A, van de Velde C J, Melief C J
Department of Immunohaematology and Blood Bank, University Hospital Leiden, The Netherlands.
Br J Cancer. 1995 Sep;72(3):637-41. doi: 10.1038/bjc.1995.386.
Mutation of the p53 gene is a common event in colorectal cancer. This alteration can result in cellular accumulation of p53 and may also induce p53 antibodies. Accumulation of p53 in tumour cells has been associated with poor prognosis of colorectal cancer. We tested preoperative sera from 255 patients with colorectal cancer by enzyme-linked immunosorbent assay (ELISA). A total of 70.2% had reactivity that was higher than the 'low' control serum. Employing a cut-off level of 10% of the 'high' control sample, 25.5% of the patients were positive for p53 antibodies. The presence of p53 antibodies correlated with the following prognostic factors: histological differentiation grade, shape of the tumour, and tumour invasion into blood vessels. Patients with p53 antibodies were shown to have decreased survival and decreased disease-free survival. Specifically for patients with cancer stage A and B1 the presence of p53 antibodies selected a subgroup with poor prognosis.
p53基因的突变在结直肠癌中是常见事件。这种改变可导致p53在细胞内积聚，还可能诱导p53抗体产生。肿瘤细胞中p53的积聚与结直肠癌的不良预后相关。我们采用酶联免疫吸附测定（ELISA）检测了255例结直肠癌患者的术前血清。共有70.2%的患者反应性高于“低”对照血清。以“高”对照样本的10%为临界值，25.5%的患者p53抗体呈阳性。p53抗体的存在与以下预后因素相关：组织学分化程度、肿瘤形态以及肿瘤血管浸润情况。有p53抗体的患者生存期缩短，无病生存期也缩短。特别是对于A期和B1期癌症患者，p53抗体的存在筛选出了预后不良的亚组。
